Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. (Nasdaq: EQ) is a La Jolla, California–based clinical-stage biotechnology company that publicly describes its focus as developing novel therapies for severe autoimmune and inflammatory disorders. News about Equillium often centers on the progress of its lead candidate EQ504, an investigational aryl hydrocarbon receptor (AhR) modulator, and on corporate actions that support its development strategy.
Readers of this EQ news page can follow company announcements on clinical and preclinical plans for EQ504, including preparations for Phase 1 studies in ulcerative colitis and related gastrointestinal conditions, as well as potential applications in inflammatory lung or pulmonary diseases. Equillium’s press releases also highlight scientific and translational updates, such as key opinion leader events discussing AhR modulation, intestinal inflammation and the unmet medical need in ulcerative colitis.
In addition to pipeline news, Equillium regularly reports on financing transactions like private placements and at-the-market offerings, which it links to funding the development of EQ504 and extending its operating runway. Corporate governance and leadership updates, including changes in board composition, committee membership and senior roles, are disclosed through both SEC filings and news releases.
Another recurring topic in Equillium’s news flow is its cryptocurrency treasury reserve strategy, which the company has described as part of its broader financial and growth objectives. Updates in this area appear alongside information on cash resources, investment policy changes and strategic priorities.
Investors and observers can use this news feed to monitor Equillium’s clinical plans, scientific positioning around AhR modulation, capital-raising activities, Nasdaq listing developments and treasury strategy, all of which shape the company’s path as a clinical-stage biotech focused on immuno-inflammatory diseases.
Equillium, a clinical-stage biotech company, announced its participation in the Jefferies Virtual Healthcare Conference, scheduled for June 1-4, 2021. CEO Bruce Steel and Dr. Dolca Thomas will discuss ongoing clinical programs for itolizumab, targeting severe autoimmune disorders, including acute graft-versus-host disease, lupus/lupus nephritis, and uncontrolled asthma. The presentation is set for June 2 at 11:00 AM ET, accessible via a live webcast on their website, with an archived replay available for 90 days.
Equillium, Inc. (Nasdaq: EQ) announced the presentation of three posters at the 2021 AAI Annual Meeting, showcasing the novel mechanism of action of itolizumab. This first-in-class monoclonal antibody targets the CD6-ALCAM pathway to modulate T cell responses, which are crucial in autoimmune diseases. Key findings include significant reductions in pro-inflammatory cytokine secretion and the development of a pharmacodynamic biomarker assay to monitor CD6 levels in patients. The research underscores the potential of itolizumab in treating conditions like aGVHD and lupus.
Equillium, Inc. (Nasdaq: EQ) reported positive results from its Phase 1b EQUALISE study in systemic lupus erythematosus, showing safety and a dose-dependent reduction in CD6 expression on T cells. The company raised $29.9 million from a direct offering, boosting its cash reserves to $104.1 million, sufficient to fund operations into late 2023. R&D expenses rose to $5.9 million, increasing the net loss to $9.0 million for Q1 2021, compared to $7.8 million last year. Upcoming data catalysts for 2021 include topline results from the EQUATE study and interim data from the EQUALISE study.
Equillium, Inc. (Nasdaq: EQ) announced positive data from its EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD). An abstract detailing these results has been accepted for oral presentation at EHA2021 on June 11, 2021. The study involves 10 patients with Grade III-IV aGVHD and aims to evaluate safety and efficacy. Itolizumab is designed for first-line treatment of aGVHD, a condition with no approved therapies. The observed benefit-risk profile supports further randomized trials to establish its clinical potential.
Equillium, Inc. (Nasdaq: EQ) announced the presentation of three posters at the 2021 American Association of Immunologists Annual Meeting. These posters focus on itolizumab, a drug targeting the CD6-ALCAM pathway, and its effects on T cell modulation. Key presentations include an assay to monitor CD6 engagement as a biomarker, emphasizing its role in treating autoimmune disorders. The posters will be presented on May 10 and May 14, 2021, showcasing itolizumab’s mechanism and potential clinical applications in conditions like lupus and graft-versus-host disease.
Equillium, Inc. (Nasdaq: EQ) announced positive topline results from its EQUALISE study, evaluating itolizumab for systemic lupus erythematosus (SLE). Administered subcutaneously, itolizumab was found safe and well tolerated, demonstrating a dose-dependent reduction in cell surface CD6 on effector T cells, indicating drug activity. Adverse events were primarily mild to moderate injection site reactions. The study included two groups: Type A for SLE and Type B for lupus nephritis. The complete data set from Type A will be presented at a future conference, with interim Type B data expected later this year.
Equillium, Inc. (Nasdaq: EQ) reported a net loss of $29.8 million for 2020, or $(1.46) per share, an increase from a $25.6 million loss in 2019. R&D expenses rose to $19.4 million, reflecting increased headcount and research costs. In 2021, the company announced positive interim data from the EQUATE study for aGVHD and raised $83.7 million in 2020, extending its cash runway into the second half of 2023. Upcoming data from clinical studies in lupus, uncontrolled asthma, and aGVHD is anticipated in 2021, signaling potential growth catalysts for stakeholders.
Equillium, Inc. (Nasdaq: EQ) announced positive results from its EQUATE study on itolizumab, a treatment for acute graft-versus-host disease (aGVHD). Most patients achieved a complete response within 15 days, maintained through day 85, with a significant 91% reduction in corticosteroid use. The study highlights itolizumab's potential as a first-line treatment, underlining its dose-dependent effectiveness in inhibiting pathogenic T cell proliferation. Translational data supports its role in modulating T cell activity, indicating promising future applications in severe autoimmune disorders.
Equillium, Inc. (Nasdaq: EQ) announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9, 2021. Jason Keyes, the Chief Financial Officer, will discuss ongoing clinical programs targeting acute graft-versus-host disease, lupus/lupus nephritis, and uncontrolled asthma. Attendees can engage in one-on-one meetings with Equillium's leadership during the event. A webcast of the presentation will be accessible for 90 days on their website. Equillium specializes in developing treatments for severe autoimmune disorders.
Equillium, Inc. (Nasdaq: EQ) announced its participation in the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021. The presentation will take place on February 25 at 11:20 AM ET, covering ongoing clinical programs for itolizumab in treating severe autoimmune disorders, including acute graft-versus-host disease and lupus. A live webcast will be available on the company’s website, with an archived replay accessible for 90 days. Equillium focuses on developing innovative treatments for severe immuno-inflammatory diseases.